Angiotensin Therapeutics Inc.
Evanston, IL
- UEI
- XWRYH6QN8JC5
- CAGE
- 8CHR0
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1001 Maple Ave, Evanston, IL 60202, USA
- Website
- angiotx.com
- Founded
- 2018
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| AGT001 for delayed graft function in kidney transplantation - project summary delayed graft function (DGF) is a form… | National Institute of Diabetes and Digestive and Kidney Diseases | $314,355 | |
| AGT001 for scleroderma kidney - summary systemic sclerosis is an autoimmune disease that affects predominately… | National Institute of Diabetes and Digestive and Kidney Diseases | $591,488 | |
| Lung delivery of novel ACE2 variants for covid-19 - project summary systemically administered soluble native ACE2 is… | National Heart Lung and Blood Institute | $899,526 |
About Angiotensin Therapeutics Inc.
Angiotensin Therapeutics Inc. is a for-profit corporate entity located in Evanston, Illinois, focused on developing innovative bioengineered therapeutic solutions targeting enzyme-related medical conditions. The company specializes in developing soluble enzyme variants, particularly focusing on modifications of Angiotensin Converting Enzyme 2 (ACE2), with potential applications across multiple complex medical domains including kidney diseases, transplantation complications, and viral infections. Registered in SAM.gov since March 2019, the company appears to be a research-oriented biotechnology firm dedicated to advancing novel therapeutic approaches through advanced protein engineering techniques.
The company has secured multiple federal grants from prestigious national health institutes, demonstrating its research capabilities across diverse medical challenges. Specifically, Angiotensin Therapeutics Inc. has received project grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart Lung and Blood Institute, totaling approximately $610,000 in recent awards. Their research has concentrated on developing bioengineered soluble ACE2 proteins (AGT001 and AGT002) to address critical medical conditions, including scleroderma kidney complications, delayed graft function in kidney transplantation, and potential COVID-19 interventions. The grants support preclinical research using transgenic mouse models to evaluate the effectiveness of their engineered enzyme variants in treating complex medical conditions, with a particular emphasis on reducing inflammatory processes, preventing organ injury, and exploring potential therapeutic interventions for challenging diseases with limited existing treatment options.
Quick answers
What is Angiotensin Therapeutics Inc.'s UEI?
Angiotensin Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is XWRYH6QN8JC5.
What is Angiotensin Therapeutics Inc.'s CAGE code?
Angiotensin Therapeutics Inc.'s CAGE code is 8CHR0.
Where is Angiotensin Therapeutics Inc. located?
Angiotensin Therapeutics Inc.'s physical address in SAM.gov is 1001 Maple Ave, Evanston, IL 60202, USA.
Is Angiotensin Therapeutics Inc. registered in SAM.gov?
Yes. Angiotensin Therapeutics Inc.'s SAM.gov registration is active through September 4, 2027.
What is Angiotensin Therapeutics Inc.'s most recent federal award?
Angiotensin Therapeutics Inc.'s most recent federal grant award is AGT001 for delayed graft function in kidney transplantation - project summary delayed graft function (DGF) is a form… (R41DK142544), from National Institute of Diabetes and Digestive and Kidney Diseases, on September 15, 2025.
On GovTribe
See Angiotensin Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors